Oncology Clinical Research Consulting
Solutions Designed for Across the Drug Development Cycle
Aptus is a leading clinical consultancy business which specilises within oncology product development. Aptus is designed to offer truly creative and flexible solutions for clinical development projects. Our focus is to deliver innovative technologies, collaborative and experienced staff, excellence and efficiency in delivery. We are committed to supporting new products and ensuring they start their development journey in an optimal position to reach the market and be the Catalyst to changing lives.
Aptus and Catalyst are highly customer focused aiming to offer bespoke solutions from initial ad-hoc support right through to full-service CRO delivery should a client wish. Our Oncology focus enables us to truly understand the unique needs and challenges in this field and guide you though the process. We are able to offer scientific and industry experience in a collaborative approach by truly listening to our clients and supporting them to succeed.
How We Work
Aptus offers a bespoke clinical research consultancy solutions, specailisng in oncology. Focused on streamlining project and resource management to support you in building solid foundations to ensure optimal results during conduct and delivery. In May 2022 Aptus partnered with Catalyst Clinical Research to deliver global projects whilst continuing to offer all its services.
Aptus was founded in 2014 and has spent most of its history focused on the delivery of CRO solutions. Following Aptus' acquisition by Catalyst Clinical Research Aptus evolved and expanded its clinical consultancy solution with the aim of supporting potentially life-changing therapies in getting to their First-in-Human studies and beyond.
Examples of our solutions
Optimal design and execution of are critical for de-risking of clinical development programmes and achieving regulatory success.
- Initial project planning workshops
- Planning of early clinical development programmes, from preclinical research through to the proof of concept studies
- Design of early clinical trials, e.g. dose escalation studies in healthy volunteers and patients, drug-drug interaction studies, etc.
- Regulatory advice meetings for various approval boards
- ILAP & TDP experience for UK specific studies